The era of molecular-based targeted therapy in lung cancer can be said to have started with the identification of activating oncogenic mutations in the epidermal growth factor receptor (EGFR) in NSCLC and subsequent development of the tyrosine kinase inhibitor gefitinib as treatment (27). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.